Afuco™ Anti-Human CLEC12A ADCC Recombinant Antibody, ADCC Enhanced (CAT#: AFC-161CL)
Anti-CLEC12A ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. This is an antibodiy that specifically bind to human CLL-1, in particular to the extracellular domain of a CLL-1 expressing cell. The CLL-1 antibodies can inhibit cancer cell growth (proliferation and/or engraftment) and thus can be considered chemotherapeutic agents alone.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.

(Glandular cells Staining: Low Intensity: Weak Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/48515/114818_A_7_3.jpg

(Cells in tubules Staining: Low Intensity: Weak Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/48515/114818_A_7_5.jpg

(Hematopoietic cells Staining: High Intensity: Strong Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/48515/114818_B_5_4.jpg

(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas v21.proteinatlas.org/ENSG00000172322-CLEC12A
Specifications
- Host Species
- Human
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Related Disease
- Hematologic malignancies
Product Property
- Purity
- >97%, by SDS-PAGE under reducing conditions
- Storage
- Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.
Target
- Alternative Names
- CLEC12A; C-type lectin domain family 12, member A; CLL1; MICL; CLL-1; DCAL-2; C-type lectin domain family 12 member A; C-type lectin protein CLL-1; C-type lectin-like molecule-1; dendritic cell-associated lectin 2; myeloid inhibitory C-type lectin-like receptor
- Gene ID
- 160364
- UniProt ID
- Q5QGZ9
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "CLEC12A"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1855z | Mouse Anti-CLEC12A Recombinant Antibody (clone 31C4) | FC | Mouse IgG2b |
MOB-150CQ | Mouse Anti-CLEC12A Recombinant Antibody (clone YC026) | FC | Mouse IgG2a, κ |
HPAB-2073LY | Mouse Anti-CLEC12A Recombinant Antibody (HPAB-2073LY) | ELISA, FC | Mouse IgG |
HPAB-2074LY | Human Anti-CLEC12A Recombinant Antibody (HPAB-2074LY) | ELISA, FC | Human IgG |
HPAB-2075LY | Mouse Anti-CLEC12A Recombinant Antibody (HPAB-2075LY) | ELISA, FC | Mouse IgG |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-161CL. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, WB
Application: WB, IHC, FC, Cyt, ELISA
Application: WB, Neut, FuncS
Application: WB, ELISA, FC, IHC, IF, IP
Application: ELISA, IHC, IF, IP, FC, FuncS
Application: Neut, IHC, Activ, FuncS, IF, ELISA
Application: ELISA, IHC, WB
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.